TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Radient
Pharmaceuticals Corporation (OTCQX:RXPC.PK- News) (OTCPK:RXPC.PK- News), a
developer and marketer of cancer tests, today announces it
has expanded its distribution agreement with UniPharma Taiwan
headquartered in Taipei, Taiwan.
Previously, Radient's agreement with Uni Pharma provided
UniPharma the exclusive right to distribute Radient's
flagship product Onko-Sure® cancer test in Taiwan. Radient
and UniPharma have now expanded the territory to include
Singapore, Hong Kong and Macau. As a full-service
distribution partner, UniPharma handles regulatory approvals
in assigned territories. Onko- Sure® is a non-invasive in
vitro diagnostic blood biomarker test for cancer.
Uni Pharma will be receiving its first shipment of test kits
this month, December 2011.
With a combined population of over 35 million people, Taiwan,
Singapore, Hong Kong, and Macau is a significant health care
market. Cancer remains the leading cause of death in Taiwan,
according to the latest statistics released by the Taiwan
Department of Health on June 15, 2011 (Taiwan Today, June 16
2011). The most prevalent types of cancer are lung cancer,
liver cancer and colorectal cancer, the three of which were
responsible for over half of all cancer deaths in Taiwan.
"Onko-Sure® is a cost effective, high value In Vitro
Diagnostic cancer test that should be included as a valuable
diagnostic tool by doctors, clinicians, and other oncology
healthcare professionals," stated Terry Lin, General Manager
of UniPharma. "The UniPharma team is excited to distribute
Onko-Sure® in our assigned territories of Taiwan and now
Singapore, Hong Kong, and Macau. UniPharma has increased its
medical sales team and committed to present at upcoming
regional cancer conferences to increase awareness of
Onko-Sure®. UniPharma has already launched its first
Onko-Sure outreach campaign with a booth at the Taiwan
Colorectal Cancer Conference at the Taiwan International
Convention Center (December 9-11) in Taipei."
"Radient welcomes UniPharma's increased commitment to
Onko-Sure®," said the Company's
Chairman and CEO, Douglas MacLellan. "We look forward to a
continued, successful working relationship as UniPharma
advocates the use of Onko-Sure in these important health care
markets."
Founded in 1998, UniPharma was established by a group of professional managers with multi- national pharmaceutical company backgrounds and extensive experience in the pharmaceutical industry. Uni Pharma is dedicated to supplying the best products to patients and delivering the most value to its partners. Uni Pharma distributes pharmaceutical and medical device products in Taiwan for nine international firms from seven countries across the globe. For more information, visit http://www.uni-pharma.com/gyhyenglish.html.
About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA- cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. Diagnostics are the key to informed treatment decisions; identifying the right treatment for the right patient can make all the difference, particularly in cancer patients. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995: The statements contained in this document
include certain predictions and projections that may be
considered forward-looking statements under securities law.
These statements involve a number of important risks and
uncertainties that could cause actual results to differ
materially including, but not limited to, the performance of
joint venture partners, as well as other economic,
competitive and technological factors involving the
Company's operations, markets, services, products, and
prices. With respect to Radient Pharmaceuticals Corporation,
except for the historical information contained herein, the
matters discussed in this document are forward-looking
statements involving risks and uncertainties that could cause
actual results to differ materially from those in such
forward-looking statements.
For additional information on Radient Pharmaceuticals
Corporation and its products visit:
www.radient-pharma.comor www.onko-sure.comor e-mail info@radient-pharma.com.
For
Investor Relations contact Paul Knopick at: pknopick@eandecommunications.comor 949-707-
5365.
distribué par | Ce noodl a été diffusé par Radient Pharmaceuticals Corporation et initialement mise en ligne sur le site http://www.radient-pharma.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2011-12-22 20:16:18 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
RADIENT PHARMA Expands Distribution Of Onko-Sure® In Asia; Receives Payment On First Order Of 60 Kits |